SECOND REGULAR SESSION
SENATE BILL NO. 751
102ND GENERA L ASSEMBLY
INTRODUCED BY SENATOR BROWN (16).
4271S.01I KRISTINA MARTIN, Secretary
AN ACT
To amend chapter 376, RSMo, by adding thereto three new sections relating to insurance coverage
of pharmacy services.
Be it enacted by the General Assembly of the State of Missouri, as follows:
1 Section A. Chapter 376, RSMo, is amended by adding thereto
2 three new sections, to be known as sections 376.411, 376.414,
3 and 376.415, to read as follows:
1 376.411. 1. For purposes of this section, the
2 following terms mean:
3 (1) "Clinician-administered drug", any legend drug, as
4 defined in section 338.330, that is administered by a health
5 care provider who is authorized to administer the drug;
6 (2) "Health carrier", the same meaning given to the
7 term in section 376.1350;
8 (3) "Participating provider", the same meaning given
9 to the term in section 376.1350;
10 (4) "Pharmacy benefits manager", the same meaning
11 given to the term in section 376.388.
12 2. A health carrier, a pharmacy benefits manager, or
13 an agent or affiliate of such health carrier or pharmacy
14 benefits manager shall not:
15 (1) Impose any penalty, impediment, differentiation,
16 or limitation on a participating provider for providing
17 medically necessary clinician-administered drugs regardless
18 of whether the participating provider obtains such drugs
SB 751 2
19 from a provider that is in the network including, but not
20 limited to, refusing to approve or pay or reimbursing less
21 than the contracted payment amount;
22 (2) Impose any penalty, impediment, differentiation,
23 or limitation on a covered person who is administered
24 medically necessary clinician-administered drugs regardless
25 of whether the participating provider obtains such drugs
26 from a provider that is in the network including, but not
27 limited to, limiting coverage or benefits; requiring an
28 additional fee, higher co-payment, or higher coinsurance
29 amount; or interfering with a patient's ability to obtain a
30 clinician-administered drug from the patient's provider or
31 pharmacy of choice by any means including, but not limited
32 to, inducing, steering, or offering financial or other
33 incentives; or
34 (3) Impose any penalty, impediment, differentiation,
35 or limitation on any pharmacy, including any class B
36 hospital pharmacy as defined in section 338.220, that is
37 dispensing medically necessary clinician-administered drugs
38 regardless of whether the participating provider obtains
39 such drugs from a provider that is in the network including,
40 but not limited to, requiring a pharmacy to dispense such
41 drugs to a patient with the intention that the patient will
42 transport the medication to a health care provider for
43 administration.
44 3. The provisions of this section shall not apply if
45 the clinician-administered drug is not otherwise covered by
46 the health carrier or pharmacy benefits manager.
1 376.414. 1. For purposes of this section, the
2 following terms mean:
3 (1) "340B drug", a drug that is:
SB 751 3
4 (a) A covered outpatient drug as defined in Section
5 340B of the Public Health Service Act, 42 U.S.C. Section
6 256b, enacted by Section 602 of the Veterans Health Care Act
7 of 1992, Pub. L. 102-585; and
8 (b) Purchased under an agreement entered into under 42
9 U.S.C. Section 256b;
10 (2) "Covered entity", the same meaning given to the
11 term in Section 340B(a)(4) of the Public Health Service Act,
12 42 U.S.C. Section 256b(a)(4);
13 (3) "Health carrier", the same meaning given to the
14 term in section 376.1350;
15 (4) "Pharmacy", an entity licensed under chapter 338;
16 (5) "Pharmacy benefits manager", the same meaning
17 given to the term in section 376.388;
18 2. A health carrier, a pharmacy benefits manager, or
19 an agent or affiliate of such health carrier or pharmacy
20 benefits manager shall not discriminate against a covered
21 entity or a pharmacy including, but not limited to, by doing
22 any of the following:
23 (1) Reimbursing a covered entity or pharmacy for a
24 quantity of a 340B drug in an amount less than it would pay
25 to any other similarly situated pharmacy that is not a
26 covered entity or a pharmacy for such quantity of such drug
27 on the basis that the entity or pharmacy is a covered entity
28 or pharmacy or that the entity or pharmacy dispenses 340B
29 drugs;
30 (2) Imposing any terms or conditions on covered
31 entities or pharmacies that differ from such terms or
32 conditions applied to other similarly situated pharmacies or
33 entities that are not covered entities on the basis that the
34 entity or pharmacy is a covered entity or pharmacy or that
35 the entity or pharmacy dispenses 340B drugs including, but
SB 751 4
36 not limited to, terms or conditions with respect to any of
37 the following:
38 (a) Fees, chargebacks, clawbacks, adjustments, or
39 other assessments;
40 (b) Professional dispensing fees;
41 (c) Restrictions or requirements regarding
42 participation in standard or preferred pharmacy networks;
43 (d) Requirements relating to the frequency or scope of
44 audits or to inventory management systems using generally
45 accepted accounting principles; and
46 (e) Any other restrictions, conditions, practices, or
47 policies that, as specified by the director of the
48 department of commerce and insurance, interfere with the
49 ability of a covered entity to maximize the value of
50 discounts provided under 42 U.S.C. Section 256b;
51 (3) Interfering with an individual's choice to receive
52 a 340B drug from a covered entity or pharmacy, whether in
53 person or via direct delivery, mail, or other form of
54 shipment, by any means including, but not limited to,
55 modifying a patient's payment limitations or cost-sharing
56 obligations on the basis of participation, in whole or in
57 part, in the 340B drug pricing program;
58 (4) Discriminating in reimbursement to a covered
59 entity or pharmacy based on the determination or indication
60 a drug is a 340B drug;
61 (5) Requiring a covered entity or pharmacy to
62 identify, either directly or through a third party, a 340B
63 drug sooner than forty-five days after the point of sale of
64 the 340B drug;
65 (6) Refusing to contract with a covered entity or
66 pharmacy for reasons other than those that apply equally to
SB 751 5
67 entities that are not covered entities or similarly situated
68 pharmacies, or on the basis that:
69 (a) The entity is a covered entity; or
70 (b) The entity or pharmacy is described in any of
71 subparagraphs (A) to (O) of 42 U.S.C. Section 235b(a)(4);
72 (7) Denying the covered entity the ability to purchase
73 drugs at 340B program pricing by substituting a rebate
74 discount;
75 (8) Refusing to cover drugs purchased under the 340B
76 drug pricing program; or
77 (9) Requiring a covered entity or pharmacy to reverse,
78 resubmit, or clarify a 340B drug pricing claim after the
79 initial adjudication unless these actions are in the normal
80 course of pharmacy business and not related to 340B drug
81 pricing, except as required by federal law.
82 3. A pharmaceutical manufacturer or an agent or
83 affiliate of such manufacturer shall not deny, restrict,
84 prohibit, or otherwise discriminate against, either directly
85 or indirectly, the acquisition by or delivery of a 340B drug
86 to a pharmacy that is under contract with a covered entity
87 to receive and dispense 340B drugs on behalf of the covered
88 entity. Any violation of this subsection shall be an
89 unlawful practice within the meaning of section 407.020, and
90 any action authorized in sections 407.010 to 407.130 may be
91 taken.
92 4. The director of the department of commerce and
93 insurance shall impose a civil penalty on any health
94 carrier, pharmacy benefits manager, or agent or affiliate of
95 such health carrier or pharmacy benefits manager that
96 violates the requirements of this section. Such penalty
97 shall not exceed five thousand dollars per violation per day.
SB 751 6
98 5. The director of the department of commerce and
99 insurance shall promulgate rules to implement the provisions
100 of this section. Any rule or portion of a rule, as that
101 term is defined in section 536.010, that is created under
102 the authority delegated in this section shall become
103 effective only if it complies with and is subject to all of
104 the provisions of chapter 536 and, if applicable, section
105 536.028. This section and chapter 536 are nonseverable and
106 if any of the powers vested with the general assembly
107 pursuant to chapter 536 to review, to delay the effective
108 date, or to disapprove and annul a rule are subsequently
109 held unconstitutional, then the grant of rulemaking
110 authority and any rule proposed or adopted after August 28,
111 2024, shall be invalid and void.
1 376.415. 1. For purposes of this section, the
2 following terms mean:
3 (1) "Biological product", the same meaning given to
4 the term in 42 U.S.C. Section 262(i);
5 (2) "Biosimilar", the same meaning given to the term
6 in 42 U.S.C. Section 262(i);
7 (3) "Health carrier", the same meaning given to the
8 term in section 376.1350;
9 (4) "Pharmacy benefits manager", the same meaning
10 given to the term in section 376.388;
11 (5) "Reference product", the same meaning given to the
12 term in 42 U.S.C. Section 262(i).
13 2. A health carrier, a pharmacy benefits manager, or
14 an agent or affiliate of such health carrier or pharmacy
15 benefits manager that provides coverage for a reference
16 product or a biological product that is biosimilar to the
17 reference product shall provide coverage for the reference
18 product and all biological products that have been deemed
SB 751 7
19 biosimilar to the reference product. The scope, extent, and
20 amount of such required coverage shall be the same
21 including, but not limited to, any payment limitations or
22 cost-sharing obligations.
ïƒ¼